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Objective: The objective of this study was to review the current anatomic indications for and early results of aortouni-iliac
(AUI) devices for endovascular aneurysm repair.
Methods: A total of 128 patients receiving an Endurant (Medtronic Inc, Minneapolis, Minn) AUI device in the U.S.
Investigational Device Exemption trial (44 patients) or the Endurant Stent Graft Natural Selection Global Postmarket
Registry (84 patients) were reviewed. Preoperative computed tomography imaging of patients in the Investigational Device
Exemption trial and case report forms of Registry patients were used to determine anatomic indications. Baseline charac-
teristics and early results were compared with those of 1305 patients receiving a bifurcated (BIF) device in sister studies.
Results: The indication for the AUI device was unclear from case report forms in two Registry cases. The remaining 126
patients had a unilateral iliac occlusion in 30 (23%), a severely narrowed aortic segment in 58 (45%), severe iliac occlusive
disease in 28 (22%), severe iliac tortuosity in 29 (23%), or complex iliac aneurysms in 19 (15%). Two patients had a
previous aortobifemoral graft; 38 patients (30%) had multiple indications. The AUI cohort included more women than
the BIF group did (19% vs 10%; P < .01) and had more severe comorbidities. Successful deployment was achieved in all
AUI cases. The 30-day mortality was 2% (BIF cohort, 1%; P[ .21). More AUI patients underwent repair under general
anesthesia (81% vs 64%; P < .01), and procedures were longer (110.9 6 54.9 minutes vs 99.2 6 44.3 minutes; P[ .02).
Except for longer intensive care unit stays (19.6 6 80.0 hours vs 9.0 6 34.8 hours; P [ .01) and higher myocardial
infarction rates (4% vs 1%; P < .01), outcomes of the AUI cohort were similar to those of the BIF cohort. There were no
migrations, ruptures, fractures, or open conversions at up to 1-year follow-up.
Conclusions: The AUI conﬁguration extends endovascular aneurysm repair feasibility to several hostile anatomic condi-
tions. Despite increased comorbidities in the recipient patient population and associated higher rates of postoperative
myocardial infarction and respiratory complications, early outcomes with the new generation of AUI devices are
acceptable and comparable to those after treatment with BIF conﬁgurations. (J Vasc Surg 2014;60:1452-9.)Despite considerable early beneﬁts over open surgical
procedures, endovascular aneurysm repair (EVAR) does
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2The majority of EVAR procedures are performed with
bifurcated (BIF) devices with limbs into both iliac arteries.
The use of an aortouni-iliac (AUI) conﬁguration in conjunc-
tion with a femorofemoral crossover graft has been advo-
cated intermittently for hostile and complex distal aortic
and iliac anatomy as well as for ruptured aneurysms and
salvage of some BIF graft complications. There is a paucity
of clinical information, however, about the application and
outcomes of elective AAA repair with an AUI device, in
part owing to the lack of a speciﬁcally designed and approved
endograft for this conﬁguration in the last decade. The last
approvedAUIdevice in theUnited States, part of theAncure
(Guidant, Menlo Park, Calif) endograft family, was distrib-
uted for only 2 years before being withdrawn in 2004
as the company abandoned the AAA market.1 In recent
years, the Zenith Renu (Cook Medical, Bloomington, Ind)
stent graft was developed to salvage migrated endografts
but has been used more liberally in the repair of aortic and
iliac aneurysms.2 The recent introduction of the Endurant
AUI stent graft (Medtronic Inc, Minneapolis, Minn) for
the management of AAA provides the opportunity to
re-examine this approach and its place in our modern treat-
ment strategy through data from the U.S. Investigational
Device Exemption (IDE) trial and the Endurant Stent Graft
Natural Selection Global Postmarket Registry (ENGAGE).
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Study population. The U.S. IDE trials of the Endur-
ant system enrolled patients at 26 U.S. centers, leading to
the U.S. Food and Drug Administration approval of the
BIF device in December 2010 and of the AUI device in
April 2013. The international Global Postmarket
ENGAGE Registry initiated in March 2009 is prospectively
enrolling patients treated with an Endurant endograft in
real-world practice from 79 sites in more than 30
different countries.3 These studies were sponsored by the
device manufacturer as is standard practice for IDE studies
and postmarket registries. This review included all patients
receiving an Endurant AUI stent graft in either the IDE or
ENGAGE cohorts. Baseline characteristics and results were
compared with those of patients receiving the BIF device in
the same studies. The same comorbidity and outcome data
points were used uniformly across all cohorts.
Clinical data were obtained from audited clinical
research forms collected by the sites. The research team
at each site determined the presence or absence of a speciﬁc
background disease state on the basis of the medical history
and physical examination ﬁndings obtained at study enroll-
ment. All preoperative computed tomography scans of IDE
AUI patients stored at a core laboratory and all case report
forms of Registry patients were reviewed to determine
anatomic indications for AUI device use. Outcomes at
30-day and 1-year follow-up were collected. All sites
obtained Investigational Research Board (IRB) approval
before participation or, in the case of 16 ENGAGE sites,
provided a written statement that they had conﬁrmed with
their IRB that neither approval nor notiﬁcation was needed.
All subjects gave informed consent, approved by the IRB.
Clinical measures. Baseline characteristics included
demographic factors as well as American Society of Anes-
thesiologists (ASA) classiﬁcation and Society for Vascular
Surgery/International Society for Cardiovascular Surgery
risk classiﬁcation.4,5 Procedural data included preimplan-
tation adjunctive procedures as well as the type of anes-
thesia used, estimated periprocedural blood loss, volume of
contrast material used, total ﬂuoroscopy time, and tech-
nical measures of device deployment. Clinical results were
recorded at 30 days and 1 year, including mortality, major
adverse events, presence and type of endoleaks, stent graft
kinking/occlusion, conversion to open surgery, aneurysm
rupture, and secondary procedures. Major adverse events
for the purposes of a safety end point were deﬁned as
death, bowel ischemia, myocardial infarction, paraplegia,
procedural blood loss >1000 mL, renal failure, respiratory
failure, and stroke.
Detailed data on femoral-to-femoral bypass grafts
were not recorded consistently in the ENGAGE Registry.
Complications of femoral-to-femoral bypass grafts and
reinterventions were reported in the IDE study as
procedure-related complications.
Anatomic indications. The indications for AUI
device use were categorized as follows: unilateral iliac
occlusion, severe iliac occlusive disease, severe iliactortuosity, complex iliac aneurysms, or severely narrow or
calciﬁed aortic segment precluding deployment of two iliac
limbs (Fig, A-D). Unilateral iliac occlusion was deﬁned as a
complete occlusion of either the common or external iliac
segment or both. Severe iliac occlusive disease and severe
iliac tortuosity were deﬁned as stenosis or tortuosity that
limits the safe passage of delivery sheaths. Complex iliac
aneurysms were deﬁned as those that are multiple and large
with no suitable landing zones in the common iliac arteries
on both sides. A severely narrow or calciﬁed aortic segment
was deﬁned as a distal aortic diameter <16 mm for more
than 1 cm in length, precluding the safe deployment of two
iliac limbs.
Statistical analysis. Statistical analyses were performed
with Stata 12 (StataCorp, College Station, Tex). Contin-
uous variables are reported as means 6 standard deviation
and were compared by the Student t-test or Mann-Whitney
U test; categorical data were reported as a percentage and
compared by c2 tests. Statistical signiﬁcance was assumed
at P < .05. P values were not adjusted for multiple testing
because the tests for each of the outcomes were planned
analysis to test the research hypothesis set a priori.
RESULTS
Of the 128 AUI device patients (mean age, 73.7 6
7.9 years), 44 were enrolled in the U.S. IDE trial and 84
in the ENGAGE Registry; these patients were compared
with 1305 BIF device patients (mean age, 73.1 6
8.1 years). The U.S. IDE trial enrolled 150 patients, and
the Global Postmarket ENGAGE Registry enrolled 1155
patients.
Anatomic indications. The IDE studies do not pro-
vide a good estimate of how often an AUI device was
needed as the denominators are not known. However,
with all conﬁguration options available in the ENGAGE
Registry, an AUI conﬁguration was selected in 7% of pa-
tients on the basis of anatomic considerations (84 of
1239 patients).
The indication for the AUI device was unclear from
case report forms in two Registry cases. The remaining
126 patients had a unilateral iliac occlusion in 30 (23%),
a narrow aortic segment in 58 (45%), severe iliac occlusive
disease in 28 (22%), severe iliac tortuosity in 29 (23%), or
iliac aneurysms in 19 (15%). Two patients had a previous
aortobifemoral graft without iliac occlusions, and 38
(30%) had multiple indications (Table I).
Demographics. Baseline characteristics of the AUI
group of patients compared with the BIF group are in
Table II. The patients were similar in age, but the AUI
cohort included signiﬁcantly more women (19% vs 10%;
P < .01) and had more severe comorbidities, including an
increased incidence of cardiac disease, chronic obstructive
pulmonary disease, carotid artery disease, cerebrovascular
disease, and peripheral vascular disease. More patients in
the AUI cohort were also classiﬁed as ASA class 4 and
Society for Vascular Surgery 3 than in the BIF cohort (23%
vs 9%, P < .01, and 42% vs 34%, P ¼ .09, respectively).
Table I. Anatomic indications for aortouni-iliac (AUI)
device use
Indications for AUI device use N ¼ 128, No. (%)
Unilateral iliac occlusion 30 (23)
Narrow aorta 58 (45)
Severe iliac occlusive disease 28 (22)
Severe iliac tortuosity 29 (23)
Iliac aneurysm 19 (15)
Multiple indications 38 (30)
Fig. A, Unilateral iliac occlusion. B, A severely narrowed aortic segment. C, Severe iliac occlusive disease.D, Complex
iliac aneurysms.
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Table III. Successful deployment was achieved in all AUI
cases, but duration of total implantation time, including
both ﬂuoroscopy and femoral-femoral bypass, was signiﬁ-
cantly longer than for BIF cases (110.9 6 54.9 minutes vs
99.2 6 44.3 minutes; P ¼ .02). A greater percentage of
AUI patients underwent repair under general anesthesia
compared with the BIF patients (81% vs 64%; P < .1).
Intraoperative blood loss was higher for the AUI group
(247.8 6 259.6 mL vs 204.2 6 210.0 mL; P < .01),
although the absolute difference of less than 50 mL did not
appear to be clinically signiﬁcant.
Detailed data on femoral-to-femoral bypass grafts were
not recorded consistently in the ENGAGE Registry. In theIDE study, one patient had a pre-existing femoral-to-
femoral bypass graft, whereas all others had a new bypass
as part of the procedure. In the IDE trial, no adverse events
directly attributable to the femoral-to-femoral grafts were
reported in the ﬁrst 12 months.
Outcomes. Table IV summarizes the 30-day and 1-
year outcomes. Mean hospital days were comparable be-
tween the two groups. However, AUI patients spent more
time in the intensive care unit than BIF patients did
(19.6 6 80.0 hours vs 9.0 6 34.8 hours; P ¼ .01). Overall
30-day mortality was 2%, which was not different from the
BIF mortality of 1% (P ¼ .21). Except for higher
myocardial infarction and respiratory failure rates, 30-day
outcomes of the AUI cohort were similar to those of the
BIF cohort.
At 1 year, aneurysm-related mortality was only 2% (two
of 128) for the AUI cohort. Overall mortality illustrating
the high systemic disease burden in these patients was
11%, however, which was still comparable to that of the
BIF group (7%; P ¼ .10). The bowel ischemia rate in the
AUI group was 2% compared with <1% in patients who
received a BIF graft (P ¼ .03). This may be related to
more vascular disease and more complex iliac anatomy
and internal iliac artery exclusions in the AUI group. Simi-
larly, the myocardial infarction rate at 1 year was 6% in the
AUI group compared with 2% in the BIF cohort. There
Table II. Baseline demographics and comorbidities
AUI group (n ¼ 128) BIF group (n ¼ 1305) P value
Demographics
Female 19% (24/128) 10% (131/1305) <.01
Mean age 6 SD, years 73.7 6 7.9 73.1 6 8.1 .42
Baseline comorbidities
Tobacco use 52% (66/127) 49% (622/1275) .49
Hypertension 82% (103/126) 76% (985/1290) .18
Hyperlipidemia 74% (92/124) 63% (781/1235) .01
Diabetes mellitus 24% (31/127) 20% (251/1288) .19
Cancer 21% (26/126) 21% (275/1287) .83
Alcoholism 7% (9/127) 4% (45/1272) .04
Cardiac disease 65% (83/128) 53% (689/1304) .01
Myocardial infarction 40% (49/123) 26% (327/1259) <.01
Arrhythmia 27% (34/127) 19% (243/1278) .04
Angina 29% (37/127) 15% (192/1279) <.01
Congestive heart failure 9% (12/127) 7% (90/1273) .34
Coronary artery disease 60% (73/122) 36% (458/1267) <.01
Chronic obstructive pulmonary disease 50% (62/125) 26% (332/1287) <.01
Renal insufﬁciency 20% (25/127) 15% (189/1295) .13
Carotid artery disease 27% (30/113) 12% (134/1113) <.01
Cerebrovascular/neurologic disease 21% (27/128) 15% (189/1304) .05
Transient ischemic attack 7% (9/127) 5% (63/1293) .28
Cerebrovascular accident 5% (6/127) 5.9% (77/1299) .58
Vascular disease 73% (93/128) 37% (484/1304) <.01
Previous AAA 6% (7/128) 1% (13/1298) <.01
Previous TAAA 1% (1/123) 2% (23/1255) .18
Peripheral vascular disease 49% (61/125) 18% (233/1290) <.01
ASA classiﬁcation
Class 1 4% (5/128) 6% (75/1304) .37
Class 2 19% (24/128) 44% (570/1304) <.01
Class 3 55% (70/128) 42% (548/1304) <.01
Class 4 23% (29/128) 9% (111/1304) <.01
SVS/ISCVS classiﬁcation
SVS 0 1% (1/122) 0.0% (0/1265) <.01
SVS 1 10% (12/122) 14% (182/1265) .16
SVS 2 48% (58/122) 52% (652/1265) .40
SVS 3 42% (51/122) 34% (431/1265) .09
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiologists; AUI, aortouni-iliac; BIF, bifurcated; ISCVS, International Society for
Cardiovascular Surgery; SD, standard deviation; SVS, Society for Vascular Surgery; TAAA, thoracoabdominal aortic aneurysm.
Table III. Procedural results
Operative results AUI group (n ¼ 128) BIF group (n ¼ 1305) P value
Preimplantation coil embolization of hypogastric artery 6% (8/128) 4% (53/1305) .24
Duration of implant time 6 SD, minutes 110.9 6 54.9 99.2 6 44.3 .02
General anesthesia 81% (103/128) 64% (828/1304) <.01
Estimated blood loss 6 SD, mL 247.8 6 259.6 204.2 6 210.0 <.01
Volume of contrast material 6 SD, mL 123.5 6 59.8 132.0 6 69.6 .19
Fluoroscopy time 6 SD, minutes 19.9 6 19.3 21.2 6 12.3 .29
Freedom from intraoperative death 100% (128/128) 100% (1305/1305) NA
Freedom from type I/III endoleak 96% (123/128) 99% (1290/1300) <.01
Stent graft kinking 0% (0/128) 1% (13/1297) .26
Stent graft twisting 0% (0/128) 1% (7/1296) .42
Conversion to open surgery 0% (0/128) 0% (2/1305) .61
Aneurysm rupture 0% (0/128) 0% (1/1305) .75
AUI, Aortouni-iliac; BIF, bifurcated; NA, not applicable; SD, standard deviation.
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 6 Kiguchi et al 1455were no migrations, ruptures, fractures, or open conver-
sions up to 1 year.
No statistically signiﬁcant differences were seen in
30-day and 1-year endoleak rates among the graft con-
ﬁgurations. Both groups had comparable rates of second-
ary endovascular procedures at 30 days and 1 year. Noreinterventions were required for any of the femoral-to-
femoral bypass grafts in the IDE study up to 1 year.
The total AUI cohort’s secondary endovascular reinter-
vention rates were 2% at 30 days and 8% at 1 year
(Table V). This was similar to the BIF cohort’s rate of
5% (P ¼ .19).
Table IV. The 30-day and 1-year outcomes
AUI group (n ¼ 128) BIF group (n ¼ 1305) P value
Thirty-day outcomes
Mean hospital stay 6 SD, days 6.2 6 6.7 5.9 6 6.3 .61
Mean ICU stay 6 SD, hours 19.6 6 80.0 9.0 6 34.8 .01
Mortality 2% (3/128) 1% (14/1305) .21
Bowel ischemia 1% (1/128) 0% (4/1305) .36
Myocardial infarction 4% (5/128) 1% (13/1305) <.01
Paraplegia 0% (0/128) 0% (0/1305) NA
Procedural blood loss >1000 mL 3% (4/128) 1% (17/1305) .11
Renal failure 1% (1/128) 0% (4/1305) .36
Respiratory failure 2% (2/128) 0% (2/1305) <.01
Stroke 1% (1/128) 0% (4/1305) .53
Endoleaks 14% (17/119) 12% (150/1209) .56
Conversion to open surgery 0% (0/128) 0% (1/1305) .72
Aneurysm rupture 0% (0/128) 0% (0/1305) NA
Secondary endovascular procedure 2% (3/128) 1% (17/1305) .36
One-year outcomes
All-cause mortality 11% (14/128) 7% (91/1305) .10
Bowel ischemia 2% (2/123) 0% (4/1290) .03
Myocardial infarction 6% (7/123) 2% (23/1289) <.01
Paraplegia 0% (0/122) 0% (0/1289) NA
Procedural blood loss >1000 mL 3% (4/123) 2% (19/1289) .14
Renal failure 2% (3/123) 1% (16/1289) .27
Respiratory failure 4% (5/124) 0% (4/1290) <.01
Stroke 2% (2/123) 1% (11/1290) .39
Stent graft migration 0% (0/127) 0% (1/1289) .75
Stent graft occlusion 3% (4/127) 3% (43/1289) .91
Stent graft kinking 2% (3/127) 2% (27/1289) .84
Endoleaks 7% (9/121) 9% (112/1290) .64
Conversion to open surgery 0% (0/128) 1% (7/1305) .42
Aneurysm rupture 0% (0/128) 0% (3/1305) .59
Secondary endovascular procedure 8% (10/128) 5% (67/1305) .19
AAA diameter decrease 46% (45/99) 42% (416/996) .48
AAA, Abdominal aortic aneurysm; AUI, aortouni-iliac; BIF, bifurcated; ICU, intensive care unit; NA, not applicable; SD, standard deviation.







procedure, days Reason for secondary procedure Group
15009-002 2010-01-07 2010-01-14 7 Stent graft kink AUI (ENGAGE)
20005-009 2010-07-06 2010-07-13 7 Resolve type I endoleak AUI (ENGAGE)
05003-001 2010-11-05 2010-11-23 18 Occlusion stent graft AUI (ENGAGE)
50300-002 2010-10-05 2010-11-11 37 Stent graft occlusion AUI (ENGAGE)
11002-014 2010-07-07 2010-09-15 70 Resolve type I endoleak AUI (ENGAGE)
05001-057 2010-06-18 2010-09-03 77 Infected anastomotic aneurysm left
femoral artery
AUI (ENGAGE)
10201-029 2010-05-19 2010-08-18 91 Resolve type I endoleak AUI (ENGAGE)
10209-030 2010-07-01 2010-12-13 165 Resolve stent graft occlusion (right
iliac) by implanting surgical
axillobifemoral bypass graft
AUI (ENGAGE)
05006-020 2010-11-10 2011-05-03 174 Resolve type II endoleak, resolve
aneurysm expansion
AUI (ENGAGE)
008-010 2011-02-28 2011-12-05 280 Stenosis of AUI stent graft AUI (IDE)
ENGAGE, Endurant Stent Graft Natural Selection Global Postmarket Registry; IDE, Investigational Device Exemption.
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reduction of sac diameter at 1 year (46% in AUI cohort
and 42% in BIF cohort).
DISCUSSION
AUI devices for EVAR initially gained favor because
of simpler deployment of straight grafts compared with
BIF stent grafts when cannulation of the contralateralgate was necessary, leading to its popularity for use in
ruptured AAAs.6,7 As BIF endografts have rapidly evolved
with varying delivery proﬁles and increased trackability, the
use for AUI endografts has shifted toward overcoming
the complex anatomy of select patients with AAAs. Narrow
aortic bifurcations and iliac artery disease, including tortu-
osity, aneurysms, and stenosis, continue to limit BIF
endograft use; thus, EVAR with an AUI device with
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tant role in speciﬁc anatomic cases.8,9 Patients in this study
often had multiple indications for AUI stent use for EVAR,
but the majority had an occluded iliac artery or a small
aortic diameter that would not allow safe deployment of
two limbs required of BIF endografts. Without the avail-
ability of AUI devices, the alternative options are either
open aneurysm repair, accompanied by increased morbidity
and mortality rates in elderly patients or those with comor-
bid conditions,10,11 or forcing a BIF graft to aggressively
accommodate the difﬁcult anatomy. Neither option is
desirable, and some surgeons have opted on occasion to
occlude the contralateral limb opening of a BIF device,
effectively creating an AUI conﬁguration.
The anatomic review in this study allows a better un-
derstanding of the current usage trends in AUI devices,
and the comparison to patients with BIF grafts performed
in similar settings with similar data collection deﬁnes the
patient populations better and suggests expected outcomes
in both. Although the majority of AAA exclusions in the
ENGAGE Registry were with the BIF device, the AUI
conﬁguration was selected by operators in about 7% of pa-
tients, giving an estimate for the proportion of patients
who may beneﬁt from this conﬁguration in a general
EVAR population. It is notable that considerably more
women seem to be suitable for the AUI device than for
BIF conﬁguration EVARs, illustrating the difﬁcult iliac
anatomy exhibited in women who present for the treat-
ment of their AAAs.
Indications for the AUI conﬁguration obviously vary
among users, depending on familiarity with the device
and availability of other alternatives. Thus, recommenda-
tions for the use of an AUI device cannot be generalized
and have to be based on the clinical and anatomic setting.
The conﬁguration is clearly ideal for a unilateral iliac occlu-
sion or severe stenotic iliac disease and should be recom-
mended as a suitable option for endovascular repair with
good outcomes. The other indications identiﬁed in this re-
view, such as severe iliac tortuosity, complex iliac aneu-
rysms, and a narrow calciﬁed aortic bifurcation, are
obviously more relative indications in which the AUI
conﬁguration with femoral-to-femoral bypass can be a suit-
able alternative in the absence of other better options. The
commercial availability of AUI devices clearly provides
additional options for the treating physician.
Despite these limited but well-established indications,
limited data exist on comparative outcomes for AUI
endografts in these challenging patients, especially
compared with sister studies of BIF endografts.
Our review suggests that EVAR with AUI devices can
be highly successful technically in patients with difﬁcult
anatomy and feasible, albeit with higher myocardial infarc-
tion and respiratory complication rates, in this patient pop-
ulation with increased baseline comorbidities.
The high technical success rate and low operative mor-
tality and morbidity in this study show a signiﬁcant
improvement from earlier estimates of the AUI and BIF
device comparisons, such as the Ancure endografts. Morerecent comparisons have shown similar trends as were illus-
trated in our study. Jean-Baptiste et al reviewed midterm
results after the use of BIF and AUI conﬁgurations of the
Zenith (Cook) graft during a 4-year period: 124 patients
with an AUI conﬁguration were compared with 323 pa-
tients who received the BIF conﬁguration. Technical suc-
cess rate for the AUI conﬁguration was good at 94% but
lower than that for the BIF conﬁguration (99%; P ¼
.002). As expected, the 30-day mortality rate was margin-
ally higher in the AUI group compared with the BIF group
(3.2% vs 1.5%; P ¼ .2). With a longer observation period
than in our study, more secondary procedures were neces-
sary in the AUI cohort (11% vs in 5%; P ¼ .01).12 Similar
outcomes were reported in another midterm comparison of
AUI vs BIF conﬁguration EVARs comparing 21 patients
with the Endoﬁt AUI endograft (LeMaitre Vascular, Bur-
lington, Mass) and 86 patients with the Talent bifurcated
endograft. Small numbers aside, mortality from the AUI
conﬁguration was 1.6%.13 Although the secondary endo-
vascular reintervention rates trended higher for the AUI
group in our report, and more so compared with open
AAA repair,14 endoleaks were not signiﬁcantly different be-
tween the two cohorts, and the AUI device conﬁguration
allowed aneurysm exclusion in patients who otherwise
may not have been suitable for EVAR with a BIF device,
with similar rates of morbidity and mortality. A longer
period of observation would of course be necessary to eval-
uate these variables further.
Decreasing proﬁles, increased operative experience,
and more commercial offerings continue to improve
EVAR outcomes in challenging anatomies. Although
some techniques, such as kissing balloons in the aortic
bifurcation, and endografts such as the AFX Device (Endo-
logix, Irvine, Calif) may be suitable in smaller aortic bifur-
cations, these solutions do not address all such anatomies,
including those with occluded or severely diseased iliac ar-
teries, aneurysms, or other challenging outﬂow anatomy.15
The present series provides reassurance that use of the AUI
conﬁguration may provide a reasonable alternative for such
patients with improved outcomes over historical series.
Despite no major differences between the AUI and BIF co-
horts in ASA class 3/4 in the EVT/Guidant multicenter
trial, early results were inferior with the use of the AUI de-
vice, giving pause to operators. The current series provides
a slightly different picture: with more Endurant AUI pa-
tients classiﬁed as ASA class 3/4, similar outcomes were
achieved.1 The results are also encouraging compared
with open surgical control procedures in good-risk patients
from pooled data of IDE clinical trials, which reveal a 30-
day mortality of 1.4%.16 In addition, patients experience
a reduction in blood loss, intensive care unit length of
stay, and overall hospital stay.1
The population of AUI patients has a higher burden of
comorbid disease, and a higher proportion received a gen-
eral anesthetic, probably because of the femoral-to-femoral
bypass graft. Complications due to general anesthesia and
the increased prevalence of cardiorespiratory disease in
the baseline AUI population are likely to have contributed
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1458 Kiguchi et al December 2014to the longer stays in the intensive care unit compared with
the BIF patients. The more signiﬁcant surgical burden of
the AUI procedure as well as the increased prevalence of
preoperative cardiac ischemic disease and chronic obstruc-
tive pulmonary disease is probably responsible for the
noted increase in postoperative myocardial infarctions and
respiratory failure. The favorable results reported from
this retrospective review suggest that the AUI conﬁgura-
tion is a valid option for patients with complex aortoiliac
anatomy and may be preferable to open repair when a
BIF graft cannot be deployed. In addition, the technical
ease of deploying a one-sided device compared with a
complicated BIF modular approach should not be under-
emphasized, especially in urgent clinical scenarios including
ruptured aneurysms.17 As with all EVAR patients, follow-
up is essential to monitor graft complications. However,
in patients with AUI endografts, additional attention
should be paid to the patency and complications of
femoral-to-femoral bypass grafts. Five-year primary patency
rates of femoral-to-femoral bypass grafts placed for occlu-
sive disease range from 55.8% to 73%.18-21 In a recent
study of crossover bypasses performed for aneurysms in
conjunction with an AUI conﬁguration, primary and sec-
ondary patency rates were 98% and 100%, respectively,
with a mean follow-up of 15.8 months.9 Studies suggest
that femoral-to-femoral bypass grafts placed for aneurysmal
disease have an overall higher patency rate than those
placed for other indications,22,23 but follow-up surveillance
and secondary interventions maintain higher primary and
primary-assisted patency.24
Limitations. A signiﬁcant limitation of the study is
that the indication for use of the AUI device has been
inferred by the authors from anatomic reviews and not by
having the operators declare their reason for selecting this
modality over other available treatment options. Another
limitation is the clinical comparison of two groups that
are clinically and anatomically distinct and for which treat-
ment options are not equivalently applicable. However, the
prospectively collected data that were carefully monitored,
audited, and externally reviewed provide the opportunity
to place outcomes in perspective in these populations of pa-
tients. Furthermore, with a signiﬁcant imbalance in the
number of patients enrolled in each cohort, statistical infer-
ence is limited by type II error. In addition, more complex
statistical analysis, such as logistic regression or propensity
score matching, could not be performed as patient-
speciﬁc data for both cohorts were not coded to run such
an analysis.
CONCLUSIONS
Patients with current anatomic indications for an AUI
device do have an increased perioperative cardiac and pul-
monary morbidity, but early outcomes demonstrate the
relative safety and effectiveness of the procedure, similar
to patients treated with a BIF conﬁguration. The AUI
conﬁguration appears to extend EVAR feasibility to several
hostile anatomies that otherwise would not be easily
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